2023-508662-15-00Not yet recruitingPhase 1
RIVKAL clinical trial for the first-in-human administration of BIM2b in participants with Glioblastoma
Source: EU CTIS (euclinicaltrials.eu) · Last updated 21 Jul 2026
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- First submitted
- 24 Jul 2024
- Start date
- 15 Sept 2027
- Lead sponsor
- Beta Innov
- Diseases
- Glioblastoma
- EU CT number
- 2023-508662-15-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 36
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hopital D Instruction Des Armées Percy | Clamart | France | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.